PRESS RELEASE

Ixaka and SomaLogic enter research collaboration to develop bispecific agents for oncology

London, UK and Boulder, Colorado, 29 June 2021: Ixaka Ltd and SomaLogic today announce a research collaboration to support the development of aptamer-based bispecific therapeutics.

The collaboration will evaluate the safety and efficacy of antigen-specific SOMAmer® reagents (modified aptamers that bind tightly and specifically to protein targets) previously identified and screened by SomaLogic as potential candidates for combination with Ixaka's anti-CD3 aptamers.

Ixaka is currently developing *in vivo* CAR-T therapies using its *in vivo* gene delivery technology, which facilitates *in vivo* targeting and transduction of patient T cells. The universal *in vivo* gene modification approach relies on proprietary anti-CD3 aptamers selected by Ixaka as targeting agents, which have been applied to engineer aptamer-based BiTEs (Bi-specific T-cell engagers).

SomaLogic's antigen-specific SOMAmer reagents will now be evaluated with the intention of improving both the safety and efficacy of antibody-based bispecifics. This follows a recent *in vitro* proof-of-concept study that successfully highlighted the potential of Ixaka's cancer specific antigenxCD3 bispecific aptamers as new anticancer agents that can recruit cytotoxic T cells and induce killing of tumor cells.

Cecile Bauche, Vice President and Chief Scientific Officer at Ixaka, commented: *"We have made great progress with our anti-CD3 aptamer candidate, with recent positive data demonstrating in vitro proof of concept when combined with a cancer-specific antigenic aptamer. SOMAmer molecules are a promising new class of drug entities with the potential to accelerate development of our aptamer-based BiTEs as anti-cancer agents and help us in our mission to offer new and effective treatments for cancer."*

Renaud Vaillant, Vice President, Business Development at Ixaka, commented: *"We have been working with aptamers as potential immunotherapies since the inception of the company. We first engaged in discussion with SomaLogic 4 years ago, when the project was just an idea as part of a presentation. I am proud and excited to finally start this collaboration, which is a result of the tremendous work achieved by our team."*

In the collaboration, SomaLogic will provide SOMAmers for screening and subsequent evaluation of *in vitro* cytotoxic properties. Ixaka will lead the experiments to identify and evaluate SOMAmer candidates with high affinity and specificity. Further work will determine functional *in vitro* properties of bispecific aptamers in human cell cultures and evaluate *in vivo* anticancer efficacy in murine models.

Nebojsa Janjic, Chief Science Officer of SomaLogic, commented: *"The ability of SOMAmer reagents to bind with high specificity and affinity to any target protein makes them ideal for the development of novel therapies for oncology. We hope to expand this collaboration with Ixaka in the future to support new treatments for other therapeutic areas."*

SomaLogic's anti-tumoral SOMAmers demonstrate potential utility as the chemical addition of 'protein-like' side chains to the nucleic acid bases that comprise a SOMAmer can be used to develop molecules

with high specificity and affinity for any targeted protein, making SOMAmer candidates attractive for novel therapeutic development.

The first application of Ixaka's TNP technology is the generation of CAR T-cell therapies for haematological malignancies. However, modification of the components offers the potential to target a broad range of therapeutic cells for the treatment of many serious diseases, including cancers, genetic disorders, neurological and ocular diseases.

– ENDS –

For further information, please contact:

Ixaka

Joe Dupere, CEO

info@ixaka.com

For media enquiries

Instinctif Partners
Tim Watson / Siobhan Sanford
+44 7837 674 500 / + 44 7534 247 411
ixaka@instinctif.com

SomaLogic

Laura Mizoue
Communications Specialist
T: +1 720-417-7509

lmizoue@somalogic.com

About Ixaka

Ixaka is a cell and gene therapy company focused on using the natural powers of the body to cure disease.

Ixaka's proprietary technologies enhance the naturally therapeutic power of cells by increasing the presence of curative cells at the site of disease, or by directly modifying cells within the body to improve disease targeting and boost their restorative effect.

Ixaka's technologies – concentrated multi-cell therapies and nanoparticle therapeutics – demonstrate potential for the treatment of a broad range of serious diseases across oncology, cardiovascular, neurological and ocular diseases, and genetic disorders.

Ixaka has offices in London, UK with R&D and manufacturing operations in Seville, Spain and Paris, France and additional manufacturing capability in Frankfurt, Germany.

For more information, please visit www.ixaka.com

Connect with us: Twitter: https://twitter.com/ixaka_Ltd; LinkedIn: https://www.linkedin.com/company/ixaka-limited/

About SomaLogic

SomaLogic seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners

and users, is derived from SomaLogic's precise, proprietary, and personalized measurement of important changes in an individual's proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.